GlobeNewswire by notified

Novotech Liver Cancer Research Landscape Report Finds 1,700 Trials Initiated Globally

Share

BOSTON, June 22, 2024 (GLOBE NEWSWIRE) -- Novotech, a global full-service clinical Contract Research Organization (CRO) specializing in partnering with biotech companies to expedite the development of cutting-edge therapeutics across all phases, has today published a leading industry report, Liver Cancer - Global Clinical Trial Landscape. Liver cancer is the sixth most diagnosed cancer worldwide and the third-most common cause of cancer-related deaths.

The report highlights the ongoing investment into liver cancer research globally and the significant treatment innovations that are designed to improve outcomes for patients.

The Novotech research analyst team provides these expert reports monthly, completely free of charge. These reports offer up-to-date insights into global clinical trial activity, revealing regions that experience the highest trial volumes and the factors behind these trends. They tackle the hurdles biotech firms face in specific therapeutic areas and discuss future paths in therapy and investment trends.

Hepatocellular carcinoma (HCC) is the predominant form of liver cancer, accounting for approximately 90% of all cases. HCC typically arises in individuals with chronic liver conditions such as hepatitis virus infection, cirrhosis, certain inherited liver diseases, or exposure to aflatoxins and affects men more than women.

The Liver Cancer - Global Clinical Trial Landscape report finds that Asia had the highest incidence, contributing approximately 600,000 cases, which represented over 70% of the global burden. Within Asia, China alone reported more than 360,000 cases. Europe reported about 88,000 cases, while Africa faced significant challenges with 73,000 cases. North America saw over 48,000 cases, predominantly from the United States. 

The Novotech report shows there’s a robust clinical trial pipeline for liver cancer, with over 1,700 trials initiated since 2018. Asia-Pacific and North America are at the forefront, contributing 55% and 24% respectively, followed by Europe at 16% and ROW at 5%, with Mainland China, South Korea, Spain and the United States emerging as top destinations for conducting trials.

These trials are across all phases, with a significant focus on early and mid-phase trials in Asia-Pacific and North America (Phase I and II), compared to Europe and the ROW which showed a lower overall number of trials. This data could suggest a difference in regional approaches to clinical research, possibly influenced by factors like funding, regulatory environments, and infrastructure. 

Ongoing trials dominate globally, with Asia-Pacific leading again in ongoing and completed studies. North America and Europe closely follow, showing considerable activity in ongoing trials but fewer completed ones.

The treatment landscape for HCC is diverse and evolving. While surgical resection and liver transplantation offer the best long-term survival, many patients are unsuitable due to tumor size or liver conditions. Other treatments include traditional chemotherapy, targeted therapies like monoclonal antibodies and small molecules, and immunotherapies such as immune checkpoint inhibitors (ICIs) or tyrosine kinase inhibitors (TKIs). First-line treatments often combine atezolizumab and bevacizumab, while second-line options include lenvatinib, sorafenib, regorafenib, and cabozantinib.

Key takeaways from the report are:

  • The drug development landscape includes approximately 70 drugs in preclinical stages, 23 in research, 51 in Phase I, 37 in Phase I/II, 66 in Phase II, 17 in Phase III, and 23 marketed drugs.
  • Due to its large population and lower volume of studies, the Asia-Pacific region has lower competing trial risk with a trial density 4 times lower than that of the US and about 2 times lower than Europe.
  • The funding landscape for liver cancer research shows substantial support, particularly through public and venture capital funding. The United States ($4,898 million) and China ($3,131 million) have seen significant venture capital investments in liver cancer research between 2019 and 2023. 
  • Funding predominantly supports preclinical, Phase I, and Phase II stages, with lesser amounts for discovery, Phase III, IND/CTA filed, and marketed stages.
  • A SWOT analysis reveals strengths in multidisciplinary approaches and evolving therapies, but also highlights weaknesses like side effects and limited access to advanced treatments. Opportunities lie in precision medicine and immunotherapy, while threats include rising healthcare costs and insufficient funding for research. 

Download the report here

About NovotechNovotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit www.Novotech-CRO.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f3310a56-88d7-4e4a-a0f5-8cc9bd2779ae

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye